This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Basketball Legend Alonzo Mourning Joins Nation's Kidney Care Leaders To Voice Concern Over Proposed Cuts To Medicare's Dialysis Benefit

Leaders Warn That Proposed 12 Percent Reduction Will Lead to Facility Closures, Diminished Access and Quality

WASHINGTON, July 30, 2013 /PRNewswire-USNewswire/ -- Basketball legend Alonzo Mourning is in Washington, DC, today for meetings with policy makers and elected officials to argue against proposed cuts to Medicare's dialysis benefit -- cuts that kidney care leaders warn will have negative consequences for patient access and quality.  

Mourning, who has kidney disease and had a kidney transplant a decade ago, has become a fierce advocate for disease awareness and public policy affecting people with kidney failure.   Mourning was joined by national leaders of Kidney Care Partners, including Chairman Ron Kuerbitz, as well as CEOs of the National Kidney Foundation, the American Kidney Fund, Dialysis Patient Citizens, and Past Chair of Renal Physicians Association, who together made their case to policymakers and elected officials.  

Their issue involves a July 1 "proposed rule" by the Centers for Medicare and Medicaid Services (CMS) – the government agency that oversees Medicare – that would cut funding for dialysis by 12 percent,** or $30 dollars on each $246 payment that Medicare would have paid per treatment for calendar year 2014.

Medicare's end-stage renal disease (ESRD) benefit currently covers nearly 85 percent of the more than 400,000 Americans with kidney failure who rely on this program for their life-sustaining dialysis care. Because of patients' heavy reliance on Medicare to cover dialysis, kidney care organizations expressed unified opposition to the proposed deep cuts. According to community leaders, if the cuts are made, Medicare would fail to cover the cost for each 3-4 hour dialysis session for beneficiaries with kidney failure.  

"I came to Washington today because health care for Americans with kidney failure is an issue I care about.   And when the leaders of our country's top kidney patient organizations tell me they have a problem, then I know I have a problem, too,"  said Mourning.  "One thing is for certain: cuts this deep will have consequences, and those consequences will end up hurting patients, eliminating jobs, and reversing quality improvements that have been made in recent years."  

"On July 1, 40 years to the day that the Medicare ESRD benefit went into effect, the federal government released this proposal to dramatically cut dialysis reimbursement,"  said Ron Kuerbitz, Chairman of Kidney Care Partners.  "For the first time since the dialysis benefit went into effect, the commitment made to Americans with kidney failure is in doubt.  Today, we urge policy makers in Washington to live up to the commitment they made 40 years ago."

Patient and professional organizations across the country agree that if the proposed rule becomes final, the cuts will have a devastating impact on the nation's dialysis system, especially in some rural and inner city areas.  Kidney care leaders are urging CMS to reverse course before the rule is finalized.  

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs